Dec 20 Gensight Biologics SA :
* Gensight biologics reports sustained visual acuity gain at 78 weeks in its phase I/II study with gs010 for the treatment of leber's hereditary optic neuropathy (LHON)
* Sustained improvement of visual acuity in patients with vision loss for less than 2 years
* Confirmation of good safety and tolerability profile of GS010 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
ChargePoint secures $43 million in funding led by Siemens
SAN FRANCISCO, June 28 Electric vehicle charging station maker ChargePoint Inc said on Wednesday it had secured $43 million in financing led by German engineering group Siemens AG, bringing to a close the U.S. company's latest funding round at $125 million.